Department of Medicinal Chemistry, Merck Research Laboratories, West Point, PA 19486, USA. vbodmer@mac.com
Abstract:
A new class of indazole-derived bradykinin B(1) antagonists and their structure-activity relationships (SAR) is reported. A number of compounds were found to have low-nanomolar affinity for the human B(1) receptor and possess acceptable P-gp and pharmacokinetics properties.